Divalproex is not an antipsychotic. It is classified by the FDA as an anti-epileptic (antiseizure) drug and is widely used as a mood stabilizer. The confusion is understandable because divalproex treats some of the same conditions that antipsychotics treat, particularly bipolar disorder, and the two are sometimes prescribed together. But they belong to different drug classes and work in fundamentally different ways.
How Divalproex Is Classified
The FDA approves divalproex (sold under the brand name Depakote) for three uses: treating manic episodes in bipolar disorder, treating certain types of seizures, and preventing migraines. Its official pharmacological class is anti-epileptic drug, though clinicians commonly refer to it as a mood stabilizer when prescribing it for bipolar disorder.
A mood stabilizer is defined by specific criteria that separate it from antipsychotics. To qualify, a drug must treat acute manic or depressive episodes, prevent those episodes from returning, and critically, not trigger or worsen mood episodes in either direction. Traditional antipsychotics can actually induce depressive states and worsen the cycling pattern of bipolar disorder, which disqualifies them as true mood stabilizers under this definition. Divalproex meets these criteria, which is why it sits in a different category.
How It Works Differently From Antipsychotics
Antipsychotics primarily target dopamine receptors in the brain. They block dopamine signaling, which is what reduces psychotic symptoms like hallucinations and delusions. Atypical (newer) antipsychotics also affect serotonin receptors and influence dopamine and acetylcholine activity in areas of the brain involved in cognition.
Divalproex takes a completely different approach. It works mainly through two mechanisms. First, it blocks voltage-gated sodium channels, which slows down the rate at which neurons fire. This prevents the kind of runaway electrical activity that causes seizures and likely contributes to mood stabilization. Second, it boosts levels of GABA, the brain’s main calming neurotransmitter. It does this in two ways: by blocking the enzyme that breaks GABA down and by stimulating production of more GABA. The net effect is that neurons become less excitable overall.
Interestingly, animal research has shown that divalproex can increase dopamine activity in certain brain regions, similar to what atypical antipsychotics do. But the pathway it uses to get there is different, and it doesn’t have the direct receptor-blocking action that defines antipsychotic drugs.
Why They’re Sometimes Used Together
Divalproex and antipsychotics are frequently combined in clinical practice, particularly for bipolar disorder and for managing aggression. This is part of what creates the impression that they might be the same type of medication.
In bipolar mania, divalproex on its own performs significantly better than placebo. A large review of 31 randomized trials involving over 4,300 patients found that people taking divalproex were about 42% more likely to respond to treatment than those on placebo. Remission rates were also meaningfully higher. But severe manic episodes sometimes need additional help, and that’s where antipsychotics often enter the picture.
When it comes to schizophrenia, the picture is more nuanced. Divalproex has no evidence supporting its use as a standalone treatment for psychotic disorders. A Cochrane review found that adding divalproex to an antipsychotic showed some benefit for overall clinical response, and appeared to reduce aggression. However, the positive findings came entirely from studies where researchers knew which patients were getting the drug, which introduces bias. Two large, rigorously blinded trials found no convincing benefit for adding divalproex to antipsychotic treatment in schizophrenia. So while some clinicians use it as an add-on, the evidence is weak.
What Divalproex Treats
For acute mania in bipolar disorder, divalproex is one of the first-line options. It’s effective at bringing down the elevated mood, racing thoughts, impulsivity, and agitation that characterize manic episodes. It can be used alone or alongside other medications.
For epilepsy, it treats complex partial seizures and absence seizures, either as the primary medication or in combination with other antiseizure drugs. For migraines, it’s approved specifically for prevention, not for stopping a migraine that’s already started.
Side Effects and Serious Warnings
Divalproex carries several serious safety concerns that distinguish it from many antipsychotics. The FDA requires its strongest warning label, a black box warning, for three risks.
The first is liver damage. Fatal liver failure has occurred in patients taking divalproex, most often within the first six months of treatment. Early warning signs include unusual tiredness, weakness, facial swelling, loss of appetite, and vomiting. Children under two are at the highest risk, especially those taking multiple seizure medications or those with metabolic disorders. Patients with certain mitochondrial DNA mutations should not take it at all.
The second is harm during pregnancy. About 1 in 9 babies (roughly 11%) born to women taking divalproex during pregnancy will have a birth defect, particularly neural tube defects like spina bifida. Beyond structural birth defects, 30 to 40% of children exposed in the womb may experience developmental problems. Because of this, divalproex is contraindicated for migraine prevention in pregnant women or women of childbearing potential who aren’t using effective contraception. For epilepsy and bipolar disorder, it should only be used during pregnancy when other options have failed.
The third is pancreatitis, or inflammation of the pancreas, which can be life-threatening.
More common, less dangerous side effects include sedation and dizziness. In clinical trials comparing it to placebo as an add-on to antipsychotics, sedation was about 38% more frequent in the divalproex group. Weight gain, a well-known issue with many antipsychotics, does not appear to be significantly increased with divalproex based on trial data.
Blood Monitoring Requirements
Unlike most antipsychotics, divalproex requires periodic blood draws to check drug levels and liver function. Because the drug can cause liver damage, liver tests are recommended before starting treatment and frequently during the first six months. Blood levels of the drug itself also need to be monitored to ensure the dose is in the therapeutic range, since too little won’t work and too much increases toxicity risk. This kind of monitoring is typical of mood stabilizers and antiseizure drugs but is not standard for most antipsychotics.